4.6 Article

Glycation modulates alpha-synuclein fibrillization kinetics: A sweet spot for inhibition

期刊

JOURNAL OF BIOLOGICAL CHEMISTRY
卷 298, 期 5, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.jbc.2022.101848

关键词

-

资金

  1. Innovation Foundation Denmark [5188-00003B]
  2. BMBF (the German Federal Ministry of Education and Research)
  3. Lundbeck Foundation [R276-2018-671]
  4. Novo Nordisk Foundation [NNFSA170028392, NNF17OC0028806]
  5. Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy [EXC 2067/1-390729940]

向作者/读者索取更多资源

This study reveals the inhibitory effect of glycation on alpha-synuclein fibril formation and provides insights into its molecular mechanism. Glycation primarily affects the elongation of alpha-synuclein and has a modest impact on oligomerization.
Glycation is a nonenzymatic posttranslational modification (PTM) known to be increased in the brains of hyperglycemic patients. Alpha-synuclein (alpha SN), a central player in the etiology of Parkinson's disease, can be glycated at lysine residues, thereby reducing alpha SN fibril formation in vitro and modulating alpha SN aggregation in cells. However, the molecular basis for these effects is unclear. To elucidate this, we investigated the aggregation of alpha SN modified by eight glycating agents, namely the dicarbonyl compound methylglyoxal (MGO) and the sugars ribose, fructose, mannose, glucose, galactose, sucrose, and lactose. We found that MGO and ribose modify alpha SN to the greatest extent, and these glycation products are the most efficient inhibitors of fibril formation. We show glycation primarily inhibits elongation rather than nucleation of alpha SN and has only a modest effect on the level of oligomerization. Furthermore, glycated alpha SN is not significantly incorporated into fibrils. For both MGO and ribose, we discovered that a level of similar to 5 modifications per alpha SN is optimal for inhibition of elongation. The remaining sugars showed a weak but optimal inhibition at similar to 2 modifications per alpha SN. We propose that this optimal level balances the affinity for the growing ends of the fibril (which decreases with the extent of modification) with the ability to block incorporation of subsequent alpha SN subunits (which increases with modification). Our results are not only relevant for other alpha SN PTMs but also for understanding PTMs affecting other fibrillogenic proteins and may thus open novel avenues for therapeutic intervention in protein aggregation disorders.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据